Pivoting from reni-cel's collapse to a one-time CRISPR LDL therapy, with first human data as the make-or-break proof point

Editas Medicine is a clinical-stage biopharmaceutical company developing a one-time gene-editing therapy for familial hypercholesterolemia that is not yet approved.

Editas discontinued reni-cel in December 2024 after $60.7M in restructuring charges and rebuilt around EDIT-401, a one-time in vivo CRISPR therapy targeting LDL-C, Lp(a), and ApoB in heterozygous familial hypercholesterolemia. The thesis resolves on whether first-in-human data replicates the 90% LDL-C reduction seen in non-human primates, a translation that no human gene editing program in this indication has yet demonstrated. NHP-to-human translation failure is the central risk, compounded by a lipid space crowded with approved RNA and small-molecule alternatives that require no editing permanence assumption.